| Literature DB >> 32802056 |
Kangnan Mo1,2, Jinbiao Shang1,2, Kejing Wang1,2, Jialei Gu1,2, Peng Wang1,2, Xilin Nie1,2, Wendong Wang1,2.
Abstract
OBJECTIVE: We performed this study to investigate the risk factors for postoperative hypocalcemia after total thyroidectomy with central lymph node dissection (CLND). Study Design. This was a single-center prospective study based on 176 consecutive patients who underwent total thyroidectomy for papillary thyroid carcinoma. Setting. Patients were recruited between January 2016 and June 2018. Subjects and Methods. Patients who underwent bilateral (n = 155, bilateral group) and ipsilateral CLND (n = 21) after total thyroidectomy were included. The preoperative and postoperative parathyroid hormone (PTH) and calcium levels were detected. The risk factors for transient hypocalcemia were identified using logistic regression analysis and receiver operating characteristic (ROC) curve analysis.Entities:
Year: 2020 PMID: 32802056 PMCID: PMC7416261 DOI: 10.1155/2020/7189857
Source DB: PubMed Journal: Int J Endocrinol ISSN: 1687-8337 Impact factor: 3.257
Demographic, clinical, and biochemical characteristics of the 176 patients with papillary thyroid carcinoma undergoing radical operation.
| Characteristic | Value |
|---|---|
| Gender (male/female) | 39/137 |
| Age (year, median, range) | 46.00 (17–73) |
| Tumor diameter (cm, median, range) | 1.00 (0.20–5.00) |
| Duration of illness (day, median, range) | 60 (1–2920) |
| Node number (single/multi/NA) | 46/125/5 |
| Total thyroidectomy (radical operation) | |
| Bilateral CLND | 108 |
| Ipsilateral CLND | 13 |
| Bilateral CLND + bilateral cervical LND | 12 |
| Bilateral CLND + ipsilateral cervical LND | 35 |
| Ipsilateral CLND + ipsilateral cervical LND | 8 |
| Pathology | |
| Pathologic N (N0/N1/N2/N3) | 65/111/0/0 |
| Pathologic T (T1/T2/T3/T4/) | 132/16/28/0 |
| Pathology stage (I/II/III/IV) | 147/22/4/3 |
| Preoperative serum PTH (pg/ml, median, range) | 46.00 (16.52–234.9) |
| Preoperative serum Ca (mmol/l, median, range) | 2.35 (2.04–3.21) |
| POD1 serum PTH (pg/ml, median, range) | 18.00 (1.20–70.20) |
| POD1 serum Ca (mmol/l, median, range) | 2.00 (1.56–2.48) |
| Postoperative complications | |
| Convulsion | 57 |
| Numbness | 29 |
| None | 90 |
| Hypocalcemia (male/female) | |
| POD1 ( | 4/51 |
| POD3 ( | 8/51 |
| POD5 ( | 4/23 |
| POD7 ( | 2/11 |
| POD30 ( | 1/4 |
| POD90 ( | 0/4 |
| POD180 ( | 0/2 |
| POD365 ( | 0/1 |
POD1/3/5/7/30/90/180/365, postoperative day 1, 3, 5, 7, 30, 90, 180, and 365. CLND, central lymph node dissection; LND, lymph node dissection.
Figure 1Changes in serum PTH and Ca before and after total thyroidectomy: (a) PTH and (b) Ca levels in patients who developed normocalcemia; (c) PTH and (d) Ca levels in patients who developed transient hypocalcemia. ∗p < 0.05 vs. preoperative; ∗∗p < 0.01 vs. preoperative. Pre, preoperative.
The comparison between patients who developed hypocalcemia and normocalcemia on postoperative day 1.
| Variables | Hypocalcemia | Normocalcemia |
|
|---|---|---|---|
| Gender (male) | 7.84% (4/51) | 28.57% (35/125) | 0.004 |
| Age (year) | 45.00 (35∼53) | 47.00 (37.5∼53) | 0.841b |
| PTH reduction (%) | 86.19 (77.92∼91.17) | 53.01 (33.26∼75.58) | <0.001 |
| Tumor diameter (cm) | 1.30 (0.70∼2.25) | 0.90 (0.60∼1.50) | 0.028 |
| Tumor grade | 1 (1∼4) | 1 (1∼3) | 0.405b |
| Preoperative serum PTH (pg/ml) | 44.90 (37.12∼64.38) | 46.18 (37.56∼58.43) | 0.893b |
| Preoperative serum Ca (mmol/l) | 2.32 (2.23∼2.41) | 2.36 (2.29∼2.46) | 0.034 |
| POD1 serum PTH (pg/ml) | 6.35 (4.00∼11.51) | 22.06 (13.18∼31.53) | <0.001 |
| POD1 serum Ca (mmol/l) | 1.91 (1.84∼1.96) | 2.15 (2.05∼2.25) | <0.001 |
| Postoperative complications | <0.001 | ||
| Convulsion | 64.71% (33/51) | 19.20% (24/125) | |
| Numbness | 35.19% (18/51) | 9.60% (12/125) |
POD1, postoperative day 1. aDifference between groups is tested by the χ [2] test; bdifference between groups is tested by the Mann–Whitney U test.
The impact of surgical methods on the frequency of postoperative hypocalcemia and serum hormone level.
| Variable | Bilateral group | Ipsilateral group |
|
|---|---|---|---|
| Age (year) | 45.00 (37∼53) | 48.00 (41∼58) | 0.433b |
| POD1 hypocalcemia | 30.97% (48/155) | 14.29% (3/21) | 0.132a |
| Gender (male) | 5/48 | 0/3 | 1.000a |
| PTH reduction (%) | 62.20 (40.70∼83.93) | 70.35 (19.71∼87.49) | 0.943b |
| Postoperative complications | 0.645a | ||
| Convulsion | 30.97% (48/155) | 42.86% (9/21) | 0.319a |
| Numbness | 18.71% (29/155) | 0 (0/21) |
|
| None | 50.32% (78/155) | 57.14% (12/21) | 0.557a |
| Preoperative serum PTH (pg/ml) | 46.43 (37.6∼59.67) | 42.34 (32.71∼66.11) | 0.599b |
| Preoperative serum Ca (mmol/l) | 2.34 (2.27∼2.45) | 2.36 (2.33∼2.45) | 0.310b |
POD1/7/30/90/180, postoperative day 1, 7, 30, 90, and 180. aDifference between groups is tested by the χ [2] test; bdifference between groups is tested by the Mann–Whitney U test.
The risk factors for the transient hypocalcemia on postoperative day 1.
| Variable | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
|
| OR (95% CI) |
|
| OR (95% CI) |
| |
| The whole cohort ( | ||||||
| Gender | 1.268 | 3.555 (1.302–9.703) |
| 1.160 | 3.189 (0.924–11.007) | 0.067 |
| Age (year) | −0.017 | 0.983 (0.954–1.012) | 0.251 | −0.001 | 0.999 (0.961–1.039) | 0.957 |
| PTH reduction (%) | 0.047 | 1.048 (1.028–1.068) |
| 0.043 | 1.044 (1.023–1.065) |
|
| Preoperative PTH (pg/ml) | 0.002 | 1.002 (0.958–1.019) | 0.849 | −0.010 | 0.990 (0.969–1.011) | 0.337 |
| Preoperative serum Ca (mmol/L) | −1.671 | 0.188 (0.015–2.295) | 0.190 | −3.023 | 0.049 (0.001–1.786) | 0.100 |
| Tumor diameter (cm) | 0.410 | 1.507 (1.059–2.145) |
| 0.447 | 1.564 (0.981–2.496) | 0.060 |
| Surgery | 0.952 | 2.590 (0.725–9.261) | 0.143 | 1.002 | 2.722 (0.518–14.318) | 0.237 |
|
| ||||||
| Bilateral group ( | ||||||
| Gender | 1.235 | 3.440 (1.243–9.523) |
| 1.155 | 3.176 (0.907–11.113) | 0.071 |
| Age (year) | −0.015 | 0.985 (0.955–1.015) | 0.320 | 0.003 | 1.003 (0.964–1.044) | 0.883 |
| PTH reduction (%) | 0.047 | 1.048 (1.028–1.069) |
| 0.042 | 1.043 (1.022–1.064) |
|
| Preoperative PTH (pg/ml) | −0.005 | 0.995 (0.977–1.013) | 0.562 | −0.018 | 0.982 (0.960–1.004) | 0.114 |
| Preoperative serum Ca (mmol/L) | −1.123 | 0.325 (0.029–3.595) | 0.360 | −0.3024 | 0.049 (0.001–1.920) | 0.107 |
| Tumor diameter (cm) | 0.389 | 1.476 (1.032–2.111) |
| 0.465 | 1.592 (0.992–2.554) | 0.054 |
|
| ||||||
| Female patients ( | ||||||
| Age (year) | −0.016 | 0.984 (0.953–1.016) | 0.316 | −0.001 | 0.999 (0.958–1.042) | 0.964 |
| PTH reduction (%) | 0.051 | 1.053 (1.030–1.076) |
| 0.049 | 1.050 (1.026–1.075) |
|
| Preoperative PTH (pg/ml) | 0.004 | 1.004 (0.987–1.022) | 0.643 | −0.006 | 0.994 (0.972–1.016) | 0.582 |
| Preoperative serum Ca (mmol/L) | −1.784 | 0.168 (0.012–2.278) | 0.180 | −3.569 | 0.028 (0.001–1.366) | 0.071 |
| Tumor diameter (cm) | 0.446 | 1.563 (1.070–2.283) |
| 0.499 | 1.647 (1.003–2.704) |
|
|
| ||||||
| Male patients ( | ||||||
| Age (year) | −0.024 | 0.976 (0.900–1.059) | 0.558 | −0.012 | 0.988 (0.869–1.123) | 0.853 |
| PTH reduction (%) | 0.027 | 1.028 (0.988–1.069) | 0.171 | 0.023 | 1.023 (0.981–1.068) | 0.285 |
| Preoperative PTH (pg/ml) | −0.028 | 0.973 (0.909–1.041) | 0.424 | −0.051 | 0.951 (0.867–1.043) | 0.284 |
| Preoperative serum Ca (mmol/L) | 0.104 | 1.019 (0.000–31.581) | 0.984 | −0.280 | 0.756 (0.000–12.050) | 0.964 |
| Tumor diameter (cm) | 0.120 | 1.127 (0.364–3.489) | 0.836 | 0.194 | 1.215 (0.242–6.100) | 0.813 |
Figure 2The ROC curves for various patients: (a) the ROC curve analysis of PTH reduction in predicting postoperative day 1 hypocalcemia in the whole cohort (n = 176); (b) the ROC curve analysis of PTH reduction in predicting postoperative day 1 hypocalcemia in patients who underwent thyroidectomy with bilateral central lymph node dissection (bilateral group, n = 155); (c) the ROC curve analysis of the PTH decrease in predicting postoperative day 1 hypocalcemia in female patients (n = 137).
The accuracy of PTH reduction in predicting hypocalcemia and normocalcemia in the whole cohort, bilateral group, and female patients.
| Variables | Hypocalcemia | Normocalcemia |
|---|---|---|
| Whole cohorta | ||
| PTH reduction ≥ 65.58% | 44 (TP) | 39 (FP) |
| PTH reduction < 65.58% | 7 (FN) | 86 (TN) |
|
| ||
| Bilateral groupb | ||
| PTH reduction ≥ 71.00% | 38 (TP) | 25 (FP) |
| PTH reduction < 71.00% | 10 (FN) | 82 (TN) |
|
| ||
| Female patientsc | ||
| PTH reduction ≥ 71.00% | 38 (TP) | 25 (FP) |
| PTH reduction < 71.00% | 8 (FN) | 66 (TN) |
aSensitivity, 53.01% (95% CI 41.80–63.94); specificity, 92.47% (95% CI 84.60–96.67); positive predictive value, 86.27% (95% CI 73.13–93.85); negative predictive value, 68.80% (95% CI 59.81–76.62). bSensitivity, 60.32% (95% CI 47.20–72.18); specificity, 89.13% (95% CI 80.49–94.38); positive predictive value, 79.17% (95% CI 64.60–89.04); negative predictive value, 76.64% (95% CI 67.28–84.04). cSensitivity, 60.32% (95% CI 47.20–72.18); specificity, 89.19% (95% CI 79.28–94.88); positive predictive value, 82.61% (95% CI 68.05–91.68); negative predictive value, 72.53% (95% CI 62.00–81.12). FN, false negative; FP, false positive; TN, true negative; TP, true positive.